TEX264

Summary

TEX264 (testis expressed 264, ER-phagy receptor, HGNC:30247) is a protein-coding gene on chromosome 3p21.2, encoding Testis-expressed protein 264 (Q9Y6I9). Major reticulophagy (also called ER-phagy) receptor that acts independently of other candidate reticulophagy receptors to remodel subdomains of the endoplasmic reticulum into autophagosomes upon nutrient stress, which then fuse with lysosomes for endoplasmic reticulum turnover.

Enables signaling receptor activity. Involved in protein-DNA covalent cross-linking repair. Acts upstream of or within reticulophagy. Located in several cellular components, including autophagosome membrane; endoplasmic reticulum membrane; and replication fork.

Source: NCBI Gene 51368 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 61 total
• Druggable target: yes
• MANE Select transcript: NM_015926

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30247
Approved symbol	TEX264
Name	testis expressed 264, ER-phagy receptor
Location	3p21.2
Locus type	gene with protein product
Status	Approved
Aliases	ZSIG11, FLJ13935
Ensembl gene	ENSG00000164081
Ensembl biotype	protein_coding
OMIM	620608
Entrez	51368

Gene structure

Transcript identifiers

Ensembl transcripts: 61 — 57 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000341333, ENST00000395057, ENST00000412249, ENST00000415259, ENST00000416589, ENST00000419358, ENST00000425781, ENST00000444233, ENST00000457573, ENST00000457927, ENST00000463857, ENST00000483429, ENST00000489026, ENST00000493444, ENST00000611400, ENST00000614067, ENST00000859143, ENST00000859144, ENST00000859145, ENST00000859146, ENST00000859147, ENST00000859148, ENST00000859149, ENST00000859150, ENST00000859151, ENST00000859152, ENST00000859153, ENST00000859154, ENST00000859155, ENST00000859156, ENST00000859157, ENST00000859158, ENST00000859159, ENST00000859160, ENST00000859161, ENST00000859162, ENST00000859163, ENST00000859164, ENST00000859165, ENST00000859166, ENST00000859167, ENST00000859168, ENST00000859169, ENST00000859170, ENST00000859171, ENST00000859172, ENST00000859173, ENST00000859174, ENST00000859175, ENST00000933301, ENST00000933302, ENST00000933303, ENST00000933304, ENST00000933305, ENST00000941685, ENST00000941686, ENST00000941687, ENST00000941688, ENST00000941689, ENST00000941690, ENST00000941691

RefSeq mRNA: 6 — MANE Select: NM_015926 NM_001129884, NM_001243725, NM_001243726, NM_001243727, NM_001278195, NM_015926

CCDS: CCDS2833, CCDS74945

Canonical transcript exons

ENST00000341333 — 5 exons

Exon	Start	End
ENSE00001081263	51674271	51674562
ENSE00001816617	51671252	51671288
ENSE00001941477	51703724	51704323
ENSE00003484638	51684413	51684634
ENSE00003580570	51699406	51699574

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 98.22.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 32.7451 / max 246.7435, expressed in 1820 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36773	31.2886	1818
36775	0.8709	235
36774	0.5856	304

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	98.22	gold quality
right testis	UBERON:0004534	98.10	gold quality
right adrenal gland	UBERON:0001233	96.20	gold quality
right adrenal gland cortex	UBERON:0035827	96.16	gold quality
left adrenal gland cortex	UBERON:0035825	96.14	gold quality
testis	UBERON:0000473	96.03	gold quality
left adrenal gland	UBERON:0001234	96.02	gold quality
skin of leg	UBERON:0001511	95.66	gold quality
granulocyte	CL:0000094	95.46	gold quality
mucosa of transverse colon	UBERON:0004991	95.42	gold quality
adrenal cortex	UBERON:0001235	95.27	gold quality
metanephros cortex	UBERON:0010533	95.15	gold quality
apex of heart	UBERON:0002098	95.07	gold quality
skin of abdomen	UBERON:0001416	95.05	gold quality
gall bladder	UBERON:0002110	94.74	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.62	gold quality
adrenal gland	UBERON:0002369	94.61	gold quality
body of stomach	UBERON:0001161	94.06	gold quality
minor salivary gland	UBERON:0001830	94.05	gold quality
rectum	UBERON:0001052	93.99	gold quality
right lobe of thyroid gland	UBERON:0001119	93.98	gold quality
right lobe of liver	UBERON:0001114	93.77	gold quality
stromal cell of endometrium	CL:0002255	93.70	gold quality
transverse colon	UBERON:0001157	93.66	gold quality
left lobe of thyroid gland	UBERON:0001120	93.64	gold quality
right uterine tube	UBERON:0001302	93.60	gold quality
saliva-secreting gland	UBERON:0001044	93.49	gold quality
zone of skin	UBERON:0000014	93.40	gold quality
islet of Langerhans	UBERON:0000006	92.91	gold quality
body of pancreas	UBERON:0001150	92.88	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.83

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

26 targeting TEX264, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4677-3P	99.49	67.91	1246
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-584-3P	99.35	67.69	1082
HSA-MIR-3692-5P	99.29	67.04	1421
HSA-MIR-361-3P	99.19	66.45	1381
HSA-MIR-4292	99.16	65.57	1767
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-3135B	98.61	65.33	1470
HSA-MIR-6776-5P	98.54	67.43	1304
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-4778-5P	97.96	68.06	1634
HSA-MIR-5007-5P	97.95	64.71	614
HSA-MIR-4314	97.50	67.30	1369
HSA-MIR-5192	96.89	63.35	879
HSA-MIR-6861-5P	96.23	67.19	800

Literature-anchored findings (GeneRIF, showing 4)

• TEX264, an endoplasmic reticulum (ER)resident protein, remodels subdomainsof the ER into ring-like structures inassociation with ATG8 proteins uponnutrient stress, which then fuse withlysosomes for ER turnover. (PMID:31006537)
• A long intrinsically disordered region of TEX264 is required for its ER-phagy receptor function to bridge the gap between the ER and autophagosomal membranes independently of its amino acid sequence. These results suggest that TEX264 is a major ER-phagy receptor. (PMID:31006538)
• TEX264 recognises both unmodified and SUMO1-modifed TOP1 and initiates TOP1cc repair by recruiting p97 and SPRTN. (PMID:32152270)
• TEX264 drives selective autophagy of DNA lesions to promote DNA repair and cell survival. (PMID:39265577)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tex264a	ENSDARG00000092154
mus_musculus	Tex264	ENSMUSG00000040813
rattus_norvegicus	Tex264	ENSRNOG00000013201
caenorhabditis_elegans		WBGENE00305157

Protein

Protein identifiers

Testis-expressed protein 264 — Q9Y6I9 (reviewed: Q9Y6I9)

Alternative names: Putative secreted protein Zsig11

All UniProt accessions (7): A0A087WTU3, C9J7N0, C9JHH5, C9JL43, C9JUC3, C9JXQ7, Q9Y6I9

UniProt curated annotations — full annotation on UniProt →

Function. Major reticulophagy (also called ER-phagy) receptor that acts independently of other candidate reticulophagy receptors to remodel subdomains of the endoplasmic reticulum into autophagosomes upon nutrient stress, which then fuse with lysosomes for endoplasmic reticulum turnover. The ATG8-containing isolation membrane (IM) cradles a tubular segment of TEX264-positive ER near a three-way junction, allowing the formation of a synapse of 2 juxtaposed membranes with trans interaction between the TEX264 and ATG8 proteins. Expansion of the IM would extend the capture of ER, possibly through a ‘zipper-like’ process involving continued trans TEX264-ATG8 interactions, until poorly understood mechanisms lead to the fission of relevant membranes and, ultimately, autophagosomal membrane closure. Also involved in the repair of covalent DNA-protein cross-links (DPCs) during DNA synthesis: acts by bridging VCP/p97 to covalent DNA-protein cross-links (DPCs) and initiating resolution of DPCs by SPRTN.

Subunit / interactions. Interacts (via the LIR motif) with ATG8 family proteins MAP1LC3A, MAP1LC3B, GABARAP and GABARAPL1. Interacts with VCP/p97; bridging VCP/p97 to covalent DNA-protein cross-links (DPCs). Interacts with TOP1 (when sumoylated).

Subcellular location. Endoplasmic reticulum membrane. Cytoplasmic vesicle. Autophagosome. Cytoplasm. Cytosol. Nucleus. Chromosome.

Domain organisation. The LIR motif in the cytosol-facing C-terminal region is involved in the interaction with ATG8 proteins. The disordered region is required for autophagosome binding and reticulophagy, probably via bridging the long distance between endoplasmic reticulum and autophagosome membranes, because ribosomes exist on endoplasmic reticulum membranes that attach to autophagic membranes.

RefSeq proteins (6): NP_001123356, NP_001230654, NP_001230655, NP_001230656, NP_001265124, NP_057010* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011256	Reg_factor_effector_dom_sf	Homologous_superfamily

UniProt features (15 total): compositionally biased region 3, topological domain 2, modified residue 2, mutagenesis site 2, chain 1, sequence variant 1, turn 1, transmembrane region 1, region of interest 1, short sequence motif 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
7VED	X-RAY DIFFRACTION	2.02
7VEC	X-RAY DIFFRACTION	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y6I9-F1	76.05	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 244, 239

Mutagenesis-validated functional residues (2):

Position	Phenotype
273	completely abolishes the interaction with lc3b.
276	completely abolishes the interaction with lc3b.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-114608	Platelet degranulation

MSigDB gene sets: 113 (showing top): SHEPARD_BMYB_MORPHOLINO_UP, GOCC_VACUOLAR_MEMBRANE, GOCC_SECRETORY_GRANULE, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, GOBP_MACROAUTOPHAGY, BLALOCK_ALZHEIMERS_DISEASE_UP, OCT1_03, GOBP_DNA_DAMAGE_RESPONSE, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, GOCC_AUTOPHAGOSOME, GOCC_PLATELET_ALPHA_GRANULE, GOCC_SECRETORY_VESICLE, GOCC_VESICLE_LUMEN, GOCC_PLATELET_ALPHA_GRANULE_LUMEN

GO Biological Process (5): reticulophagy (GO:0061709), protein-DNA covalent cross-linking repair (GO:0106300), DNA repair (GO:0006281), autophagy (GO:0006914), DNA damage response (GO:0006974)

GO Molecular Function (2): signaling receptor activity (GO:0038023), protein binding (GO:0005515)

GO Cellular Component (13): autophagosome membrane (GO:0000421), extracellular region (GO:0005576), nucleus (GO:0005634), replication fork (GO:0005657), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), cytosol (GO:0005829), platelet alpha granule lumen (GO:0031093), chromosome (GO:0005694), cytoplasm (GO:0005737), autophagosome (GO:0005776), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Response to elevated platelet cytosolic Ca2+	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
cytoplasm	3
intracellular membrane-bounded organelle	2
macroautophagy	1
DNA repair	1
DNA metabolic process	1
DNA damage response	1
catabolic process	1
transmembrane transport	1
process utilizing autophagic mechanism	1
cellular response to stress	1
molecular transducer activity	1
binding	1
vacuolar membrane	1
autophagosome	1
chromosome	1
endomembrane system	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
platelet alpha granule	1
secretory granule lumen	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
vacuole	1
intracellular vesicle	1

Protein interactions and networks

STRING

856 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TEX264	GABARAP	O95166	824
TEX264	CCPG1	Q9ULG6	816
TEX264	SEC62	Q99442	786
TEX264	ATL3	Q6DD88	786
TEX264	RETREG1	Q9H6L5	772
TEX264	RTN3	O95197	729
TEX264	GABARAPL2	P60520	704
TEX264	CALCOCO1	Q9P1Z2	668
TEX264	CD300C	Q08708	581
TEX264	MAP1LC3B	Q9GZQ8	557
TEX264	RETREG3	Q86VR2	548
TEX264	TAX1BP1	Q86VP1	518
TEX264	F5GZY7	F5GZY7	512
TEX264	RETREG2	Q8NC44	509
TEX264	NBR1	Q14596	508

IntAct

151 interactions, top by confidence:

A	B	Type	Score
TMEM79	TEX264	psi-mi:“MI:0915”(physical association)	0.790
TEX264	TMEM79	psi-mi:“MI:0915”(physical association)	0.790
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
GABARAPL2	TEX264	psi-mi:“MI:0915”(physical association)	0.660
MS4A3	TEX264	psi-mi:“MI:0915”(physical association)	0.600
TEX264	CERS4	psi-mi:“MI:0915”(physical association)	0.560
TEX264	LHFPL5	psi-mi:“MI:0915”(physical association)	0.560
MFF	TEX264	psi-mi:“MI:0915”(physical association)	0.560
TEX264	GPR42	psi-mi:“MI:0915”(physical association)	0.560
CLN6	TEX264	psi-mi:“MI:0915”(physical association)	0.560
SLC34A2	TEX264	psi-mi:“MI:0915”(physical association)	0.560
OPRM1	TEX264	psi-mi:“MI:0915”(physical association)	0.560
CREB3L1	TEX264	psi-mi:“MI:0915”(physical association)	0.560
FFAR3	TEX264	psi-mi:“MI:0915”(physical association)	0.560
	TEX264	psi-mi:“MI:0915”(physical association)	0.560
GPR42	TEX264	psi-mi:“MI:0915”(physical association)	0.560
ADGRG3	TEX264	psi-mi:“MI:0915”(physical association)	0.560
GJB1	TEX264	psi-mi:“MI:0915”(physical association)	0.560
CERS4	TEX264	psi-mi:“MI:0915”(physical association)	0.560
TM4SF18	TEX264	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (280): TMEM79 (Two-hybrid), TEX264 (Affinity Capture-MS), TEX264 (Affinity Capture-MS), CSNK1A1 (Affinity Capture-MS), POTEI (Affinity Capture-MS), CHEK2 (Affinity Capture-MS), SNX14 (Affinity Capture-MS), PNPLA6 (Affinity Capture-MS), PLEKHG4 (Affinity Capture-MS), TYW1B (Affinity Capture-MS), STAT1 (Affinity Capture-MS), PLD1 (Affinity Capture-MS), PLD2 (Affinity Capture-MS), UPK3BL (Affinity Capture-MS), OSBPL8 (Affinity Capture-MS)

ESM2 similar proteins: A0A494C0Z2, A0A494C191, A1L3C1, A2RRU4, A4Q9F3, A6NJR5, A6NLX3, A6NNV3, A6QM06, A6QNT4, D4A6L0, E1BBQ2, E9PGG2, O00255, O60320, O88559, P0DTA3, P0DUD1, P0DUD2, P0DUD3, P0DUD4, P0DUX0, P0DUX1, P0DV79, P29590, P40338, P56726, P97260, Q0P5I0, Q12770, Q14094, Q32L49, Q495Y7, Q5IBH6, Q5MJ68, Q5MNU5, Q5Q9Z2, Q5RDC3, Q5T848, Q69Z89

Diamond homologs: E9Q137, Q9Y6I9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 113 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Macroautophagy	7	11.4×	7e-04

GO biological processes:

GO term	Partners	Fold	FDR
mitophagy	7	23.4×	5e-06
autophagosome maturation	6	22.2×	6e-05
autophagosome assembly	6	14.2×	6e-04
macroautophagy	5	12.7×	4e-03
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	5	11.5×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1638 predictions. Top by Δscore:

Variant	Effect	Δscore
3:51684408:CCCA:C	acceptor_loss	1.0000
3:51684410:CA:C	acceptor_loss	1.0000
3:51684411:A:AG	acceptor_gain	1.0000
3:51684411:A:G	acceptor_loss	1.0000
3:51684412:G:GA	acceptor_loss	1.0000
3:51684412:G:GG	acceptor_gain	1.0000
3:51684412:GGT:G	acceptor_gain	1.0000
3:51684412:GGTGC:G	acceptor_gain	1.0000
3:51684632:AAGG:A	donor_loss	1.0000
3:51684633:AGG:A	donor_loss	1.0000
3:51684635:G:GG	donor_gain	1.0000
3:51684635:GTGA:G	donor_loss	1.0000
3:51684636:T:G	donor_loss	1.0000
3:51703715:T:A	acceptor_gain	1.0000
3:51671289:GT:G	donor_loss	0.9900
3:51674559:CATGG:C	donor_loss	0.9900
3:51674562:GGTAA:G	donor_loss	0.9900
3:51674563:G:GG	donor_gain	0.9900
3:51674563:GTA:G	donor_loss	0.9900
3:51674564:T:G	donor_loss	0.9900
3:51684411:AG:A	acceptor_gain	0.9900
3:51684411:AGGT:A	acceptor_gain	0.9900
3:51684412:GG:G	acceptor_gain	0.9900
3:51684412:GGTG:G	acceptor_gain	0.9900
3:51703719:CATA:C	acceptor_loss	0.9900
3:51703721:TA:T	acceptor_loss	0.9900
3:51703723:G:GT	acceptor_loss	0.9900
3:51703723:GGA:G	acceptor_gain	0.9900
3:51674269:A:AG	acceptor_gain	0.9800
3:51674270:G:GG	acceptor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000052044 (3:51702548 C>G), RS1000111054 (3:51688323 G>A), RS1000215953 (3:51698167 C>T), RS1000217574 (3:51686974 C>T), RS1000223926 (3:51692531 C>G), RS1000478208 (3:51698465 G>A), RS1000573578 (3:51701611 C>T), RS1000592317 (3:51691712 G>A), RS1000729407 (3:51677968 A>T), RS1000774546 (3:51691433 C>T), RS1000838089 (3:51671082 G>A,C), RS1000856631 (3:51674207 C>T), RS1000952261 (3:51670817 A>G), RS1001152234 (3:51687619 C>T), RS1001177939 (3:51693965 A>G)

Disease associations

OMIM: gene MIM:620608 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295994 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

6 potent at pChembl≥5 of 6 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.00	IC50	10	nM	CHEMBL1896972
7.82	IC50	15	nM	CHEMBL4861569
7.28	Kd	52.99	nM	CHEMBL5653589
7.27	ED50	53.94	nM	CHEMBL5653589
5.30	Kd	4956	nM	CHEMBL3752910
5.30	ED50	5044	nM	CHEMBL3752910

PubChem BioAssay actives

4 with measured affinity, of 7 total; 4 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[3-[(E)-[(4-anilino-6-morpholin-4-yl-1,3,5-triazin-2-yl)hydrazinylidene]methyl]phenyl] furan-2-carboxylate	2074093: Inhibition of TEX264 (unknown origin)	ic50	0.0100	uM
5-[benzyl(methyl)sulfamoyl]-4-chloro-2-(furan-2-ylmethylamino)benzoic acid	2074093: Inhibition of TEX264 (unknown origin)	ic50	0.0150	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149574: Binding affinity to human TEX264 incubated for 45 mins by Kinobead based pull down assay	kd	0.0530	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149574: Binding affinity to human TEX264 incubated for 45 mins by Kinobead based pull down assay	kd	4.9556	uM

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Valproic Acid	increases expression, increases methylation	2
FR900359	affects phosphorylation	1
alpha-pinene	increases oxidation, increases abundance, affects cotreatment	1
bisphenol A	increases expression	1
sodium arsenate	decreases expression	1
sodium arsenite	decreases expression	1
perfluorooctanoic acid	decreases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	increases methylation	1
nivalenol	increases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, increases oxidation	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
bisphenol S	affects expression	1
jinfukang	affects cotreatment, increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	increases expression	1
bisphenol AF	increases expression	1
Sunitinib	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Arsenic	affects methylation	1
Atrazine	increases expression	1
Vehicle Emissions	affects expression, increases abundance	1
Cadmium	increases abundance, increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118724	Binding	Binding affinity to TEX264 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

9 cell lines: 9 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1ID	H9 AAVS1-TRE3G-NGN2 RETREG3-/- RETREG2-/- RETREG1-/- TEX264-/-	Embryonic stem cell	Female
CVCL_D1IE	H9 AAVS1-TRE3G-NGN2 RETREG3-/- RETREG2-/- RETREG1-/- TEX264-/- CCPG1-/-	Embryonic stem cell	Female
CVCL_D1II	H9 AAVS1-TRE3G-NGN2 TEX264-/-	Embryonic stem cell	Female
CVCL_D1IV	H9 AAVS1-TRE3G-NGN2 RETREG3-/- RETREG2-/- RETREG1-/- TEX264-/- Keima-RAMP4	Embryonic stem cell	Female
CVCL_D1IW	H9 AAVS1-TRE3G-NGN2 RETREG3-/- RETREG2-/- RETREG1-/- TEX264-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1IX	H9 AAVS1-TRE3G-NGN2 RETREG3-/- RETREG2-/- RETREG1-/- TEX264-/- CCPG1-/- Keima-RAMP4	Embryonic stem cell	Female
CVCL_D1IY	H9 AAVS1-TRE3G-NGN2 RETREG3-/- RETREG2-/- RETREG1-/- TEX264-/- CCPG1-/- Keima-REEP5	Embryonic stem cell	Female
CVCL_D1IZ	H9 AAVS1-TRE3G-NGN2 TEX264-/- Keima-RAMP4	Embryonic stem cell	Female
CVCL_D1J0	H9 AAVS1-TRE3G-NGN2 TEX264-/- Keima-REEP5	Embryonic stem cell	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.